- Home
- Editorial
- News
- Practice Guidelines
- Anesthesiology Guidelines
- Cancer Guidelines
- Cardiac Sciences Guidelines
- Critical Care Guidelines
- Dentistry Guidelines
- Dermatology Guidelines
- Diabetes and Endo Guidelines
- Diagnostics Guidelines
- ENT Guidelines
- Featured Practice Guidelines
- Gastroenterology Guidelines
- Geriatrics Guidelines
- Medicine Guidelines
- Nephrology Guidelines
- Neurosciences Guidelines
- Obs and Gynae Guidelines
- Ophthalmology Guidelines
- Orthopaedics Guidelines
- Paediatrics Guidelines
- Psychiatry Guidelines
- Pulmonology Guidelines
- Radiology Guidelines
- Surgery Guidelines
- Urology Guidelines
Progesterone from an unexpected source may affect miscarriage risk
About twenty per cent of confirmed pregnancies end in miscarriage for reasons ranging from infection to chromosomal abnormality. But some women have recurrent miscarriages, a painful process that points to underlying issues. Clinical studies have been uneven, but some evidence shows that for women with a history of recurrent miscarriage, taking progesterone early in pregnancy might moderately improve these women's chances of carrying a pregnancy to term.
A recent study in the Journal of Lipid Research sheds some light on a new facet of progesterone signalling between maternal and embryonic tissue and hints at a preliminary link between disruptions to this signalling and recurrent miscarriage.
Progesterone plays an important role in embedding the placenta into the endometrium, the lining of the uterus. The hormone is key for thickening the endometrium, reorganizing blood flow to supply the uterus with oxygen and nutrients, and suppressing the maternal immune system.
Progesterone is made in the ovary as a normal part of the menstrual cycle, and at first, this continues after fertilization. About six weeks into the pregnancy, the placenta takes over making progesterone, a critical handoff. (The placenta also makes other hormones, including human chorionic gonadotropin, which is detected in a pregnancy test.) Placental progesterone comes mostly from surface tissue organized into fingerlike projections that integrate into the endometrium and absorb nutrients. Some cells leave those projections and migrate into the endometrium, where they help to direct the reorganization of arteries.
Using cells from terminated pregnancies, Austrian researchers led by Sigrid Vondra and supervised by Jürgen Pollheimer and Clemens Röhrl compared the cells that stay on the placenta's surface with those that migrate into the endometrium. They discovered that the enzymes responsible for progesterone production differ between the two cell types early in pregnancy.
As a steroid hormone, progesterone is derived from cholesterol. Although the overall production of progesterone appears to be about the same in migratory and surface cells, migratory cells accumulate more cholesterol and express more of a key enzyme for converting cholesterol to progesterone. Among women who have had recurrent miscarriages, that enzyme is lower in migratory cells from the placenta compared to women with healthy pregnancies. In contrast, levels of the enzyme don't differentiate between healthy and miscarried pregnancies in cells from the surface of the placenta.
The team's findings suggest that production of progesterone by the migratory cells may have a specific and necessary role in early pregnancy and that disruption to that process could be linked to miscarriage.
For more details click on the link: http://dx.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd